Table 2 Univariate analysis in relation to overall survival and disease-free survival
Patient characteristics | Overall survival | Disease-free survival | ||||
|---|---|---|---|---|---|---|
HR | 95%CI | P-value | HR | 95%CI | P-value | |
Age, years | ||||||
<60 | ||||||
≥60 | 0.954 | 0.488-1.865 | 0.891 | 0.729 | 0.431-1.234 | 0.240 |
Gender | ||||||
Female | ||||||
Male | 1.029 | 0.492-2.153 | 0.939 | 0.992 | 0.575-1.714 | 0.978 |
Tumor stage before CRT | ||||||
II | ||||||
III | 7.237 | 0.992-52.812 | 0.051 | 3.468 | 1.262-9.532 | 0.016 |
Tumor location | ||||||
Low | ||||||
Middle-high | 1.321 | 0.720-2.426 | 0.368 | 1.025 | 0.635-1.656 | 0.920 |
NLR before CRT | ||||||
Low (<2.8) | ||||||
High (≥2.8) | 2.526 | 1.384-4.610 | 0.003 | 1.662 | 1.037-2.664 | 0.035 |
Platelets count, ×10 9 /l | ||||||
<300 | ||||||
≥300 | 0.655 | 0.258-1.664 | 0.373 | 0.813 | 0.417-1.587 | 0.544 |
CEA, ng/ml | ||||||
<5 | ||||||
≥5 | 2.014 | 1.092-3.715 | 0.025 | 1.727 | 1.081-2.761 | 0.022 |
RT dose, Gy | ||||||
45-50 | ||||||
>50 | 0.801 | 0.403-1.594 | 0.527 | 0.716 | 0.432-1.185 | 0.193 |
Surgical procedure | ||||||
Curative surgery | ||||||
Palliative surgery | 2.383 | 0.994-5.713 | 0.052 | 2.2 | 1.048-4.616 | 0.037 |
Lymphatic or vascular invasion | ||||||
No | ||||||
Yes | 2.346 | 1.085-5.073 | 0.03 | 2.274 | 1.221-4.238 | 0.010 |
Neural invasion | ||||||
No | ||||||
Yes | 1.254 | 0.557-2.824 | 0.585 | 1.382 | 0.757-2.525 | 0.293 |
Circumferential resection margin | ||||||
Negtive | ||||||
Positive | 1.956 | 0.470-8.148 | 0.357 | 1.454 | 0.356-5.936 | 0.602 |
ypTNM staging | ||||||
ypT0-2 N0 | ||||||
ypT3-4/N+ | 4.223 | 1.953-9.133 | <0.001 | 4.204 | 2.337-7.562 | <0.001 |
TRG score | ||||||
0-1 | ||||||
2-3 | 1.897 | 1.031-3.491 | 0.040 | 1.714 | 1.076-2.731 | 0.023 |
Adjuvant chemotherapy | ||||||
Yes | ||||||
No | 2.354 | 0.982-5.639 | 0.055 | 1.294 | 0.592-2.826 | 0.518 |